The FDA’s anesthetic and analgesic drug committees began meeting Wednesday and are expected to conclude their discussion Thursday, regarding cardiovascular risk related to opioid receptor antagonists. Because both companies are active in this space, the FDA commentary is likely to have a significant impact on the share price of both companies.
This FDA meeting will not result in a final decision, but the recommendation from the committee will be important for the FDA’s final action.
Shares of Progenics are down 2.28 percent and Nektar shares are up 34.84 percent since the FDA announced this meeting in June 2013.
- Top Healthcare Movers For June 9, 2014
- Small Pharmaceuticals Rallying Following FDA Report
- Wider-than-Expected Q1 Loss at Nektar - Analyst Blog
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.